Recent reports highlighted racial and ethnic differences in US drug overdose deaths from 1999 to 2020.1,2 Overdose deaths increased 37.2% from February 2020 to August 2021 and were predominantly associated with synthetic opioids other than methadone (primarily fentanyl or analogs) and methamphetamine.3,4 Yet data are lacking regarding racial and ethnic disparities in overdose death rates within specific sex-age combinations before and during the COVID-19 pandemic (since March 2020).
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: August 2, 2022.
Published: September 20, 2022. doi:10.1001/jamanetworkopen.2022.32314
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Han B et al. JAMA Network Open.
Corresponding Author: Nora D. Volkow, MD, 301 N Stonestreet Ave, 3WFN Room 09D20, MSC 6025, Bethesda, MD 20892 (firstname.lastname@example.org).
Author Contributions: Dr Han had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Han, Einstein, Jones, Compton, Volkow.
Acquisition, analysis, or interpretation of data: Han, Cotto, Compton, Volkow.
Drafting of the manuscript: Han, Cotto, Volkow.
Critical revision of the manuscript for important intellectual content: Han, Einstein, Jones, Compton, Volkow.
Statistical analysis: Han.
Administrative, technical, or material support: Einstein, Jones, Cotto, Volkow.
Conflict of Interest Disclosures: Dr Compton reported long-term stock holdings with General Electric Co, 3M Companies, and Pfizer Inc outside the submitted work. No other disclosures were reported.
Funding/Support: This study was sponsored by the National Institute on Drug Abuse of the National Institutes of Health and the Centers for Disease Control and Prevention.
Role of the Funder/Sponsor: The sponsors had a role in the review and approval of the manuscript. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, the Centers for Disease Control and Prevention, and the US Department of Health and Human Services.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.